Professor Josette Eris

Clinical Associate Professor
Medicine, Central Clinical School

Telephone +61 2 9515 7648
Fax +61 2 9515 6250

Map

Selected grants

2004

  • An integrated approach to application of novel developments in basic transplantation research to cli; Chadban S, Hennessy A, Allen R, McCaughan G, Bishop A, Sharland A, Eris J; National Health and Medical Research Council (NHMRC)/Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Sud, R., Garry, L., Spicer, S., Allen, R., Eris, J., Wyburn, K., Verran, D., Cooper, C., Chadban, S. (2014). A role for everolimus in post-transplant encapsulating peritoneal sclerosis: First case report. Nephrology, 19(SUPPL. 1), 27-30. [More Information]
  • Russ, G., Tedesco-Silva, H., Kuypers, D., Cohney, S., Langer, R., Witzke, O., Eris, J., Sommerer, C., Von Zur-Muhlen, B., Woodle, E., et al (2013). Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results. American Journal of Transplantation, 13(7), 1746-1756. [More Information]
  • Chadban, S., Eris, J., Russ, G., Campbell, S., Chapman, J., Pussell, B., Trevillian, P., Ierino, F., Thomson, N., Hutchison, B., et al (2013). Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology, 18(1), 63-70. [More Information]
  • Ko, H., Yin, J., Wyburn, K., Wu, H., Eris, J., Hambly, B., Chadban, S. (2013). Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrology, Dialysis, Transplantation, 28(2), 327-336. [More Information]
  • Tedesco-Silva, H., Kho, M., Hartmann, A., Vitko, S., Russ, G., Rostaing, L., Budde, K., Campistol, J., Eris, J., Krishnan, I., et al (2013). Sotastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients. American Journal of Transplantation, 13(7), 1757-1768. [More Information]
  • Chadban, S., Barraclough, K., Campbell, S., Clark, C., Coates, P., Cohney, S., Cross, N., Eris, J., Henderson, L., Howell, M., O'Connell, P., Webster, A., Wong, G., et al (2012). KHA-CARI guideline: KHA-CARI Adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Nephrology, 17(3), 204-214. [More Information]
  • Gallagher, M., Kelly, P., Jardine, M., Perkovic, V., Cass, A., Craig, J., Eris, J., Webster, A. (2010). Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. Journal of the American Society of Nephrology, 21(5), 852-858. [More Information]
  • Hardy, J., Hambly, B., Ko, H., Wyburn, K., Eris, J., Yin, J. (2010). Stimulation of Mesangial Cells by Angiotensin II and Lipopolysaccharide Increases Expression of Interleukin-18, but Not IL-18 Receptor. Nephron Journals, 116(4), e63-e71. [More Information]
  • Gallagher, M., Jardine, M., Perkovic, V., Cass, A., McDonald, S., Petrie, J., Eris, J. (2009). Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 87(12), 1877-1883. [More Information]
  • Low, T., Clark, J., Gao, K., Eris, J., Shannon, K., O'Brien, C. (2009). Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ Journal of Surgery, 79(5), 378-382. [More Information]
  • Jardine, M., Bhandari, S., Wyburn, K., Misra, A., McKenzie, P., Eris, J. (2009). Photopheresis therapy for problematic renal allograft rejection. Journal of Clinical Apheresis, 24(4), 161-169. [More Information]
  • Ko, H., Hambly, B., Eris, J., Levidiotis, V., Wyburn, K., Wu, H., Chadban, S., Yin, J. (2008). Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transplant Immunology, 20(1-2), 99-105. [More Information]
  • Tedesco-Silva, H., Vitko, S., Pascual, J., Eris, J., Magee, J., Whelchel, J., Civati, G., Campbell, S., Alves-Filho, G., Bourbigot, B., et al (2007). 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transplant International, 20(1), 27-36. [More Information]
  • Chadban, S., Baines, L., Polkinghorne, K., Jeffreys, A., Dogra, S., Kanganas, C., Irish, A., Eris, J., Walker, R. (2007). Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. American Journal of Kidney Diseases, 49(2), 301-309. [More Information]
  • Cass, A., Cunningham, J., Anderson, K., Snelling, P., Colman, S., Devitt, J., Preece, C., Eris, J. (2007). Decision-making about suitability for kidney transplantation: Results of a national survey of Australian nephrologists. Nephrology, 12(3), 299-304. [More Information]
  • Wu, H., Chen, G., Wyburn, K., Bertolino, P., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2007). TLR4 activation mediates kidney ischemia/reperfusion injury. Journal of Clinical Investigation, 117(10), 2847-2859. [More Information]
  • Cunningham, J., Cass, A., Anderson, K., Snelling, P., Devitt, J., Preece, C., Eris, J. (2006). Australian nephrologists' attitudes towards living kidney donation. Nephrology, Dialysis, Transplantation, 21(5), 1178-1183. [More Information]
  • Salvadori, M., Budde, K., Charpentier, B., Klempnauer, J., Nashan, B., Pallardo, L., Eris, J., Schena, F., Eisenberger, U., Rostaing, L., et al (2006). FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. American Journal Of Transplantation, 6(12), 2912-2921.
  • Rose, B., Wilkins, D., Li, W., Tran, N., Thompson, C., Cossart, Y., McGeechan, K., O'Brien, C., Eris, J. (2006). Human Papillomavirus in the Oral Cavity of Patients with and without Renal Transplantation. Transplantation, 82(4), 570-573. [More Information]
  • Wyburn, K., Wu, H., Chen, G., Yin, J., Eris, J., Chadban, S. (2006). Interleukin-18 affects local cytokine expression but does not impact on the development of kidney allograft rejection. American Journal Of Transplantation, 6(11), 2612-2621. [More Information]
  • Campistol, J., Eris, J., Oberbauer, R., Friend, P., Hutchison, B., Morales, J., Claesson, K., Stallone, G., Russ, G., Rostaing, L., et al (2006). Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology, 17(2), 581-589.
  • Eris, J., Russ, G., Hutchison, B., Walker, R., Chapman, J., Pussell, B., Mahoney, J., Campbell, S., Brault, Y., Burke, J., et al (2006). Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation. Immunology and Cell Biology, 84(3), A19-A19.
  • Eris, J. (2005). Clinical experience with everolimus (Certican) in young renal transplant recipients. Transplantation, 79(9). [More Information]
  • Krämer, B., Neumayer, H., Stahl, R., Pietrzyk, M., Krüger, B., Pfalzer, B., Bourbigot, B., Campbell, S., Whelchel, J., Eris, J., et al (2005). Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplantation Proceedings, 37(3), 1601-1604. [More Information]
  • Kusyk, T., Verran, D., Stewart, G., Ryan, B., Fisher, J., Tsacalos, K., Chadban, S., Eris, J. (2005). Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation. Transplantation Proceedings, 37(2), 1026-1028. [More Information]
  • Wyburn, K., Wu, H., Yin, J., Jose, M., Eris, J., Chadban, S. (2005). Macrophage-derived interleukin-18 in experimental renal allograft rejection. Nephrology, Dialysis, Transplantation, 20(4), 699-706. [More Information]
  • Morales, J., Campistol, J., Kreis, H., Mourad, G., Eris, J., Schena, F., Grinyo, J., Nanni, G., Andres, A., Castaing, N., et al (2005). Sirolimus-Based Therapy With or Without Cyclosporine: Long-Term Follow-up in Renal Transplant Patients. Transplantation Proceedings, 37(2), 693-696. [More Information]
  • Russ, G., Segoloni, G., Oberbauer, R., Legendre, C., Mota, A., Eris, J., Grinyó, J., Friend, P., Lawen, J., Hartmann, A., et al (2005). Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. Transplantation, 80(9), 1204-1211. [More Information]
  • Yu, R., Chadban, S., Svara, F., Sen, S., Eris, J. (2005). Two cases of delayed cyclosporin absorption leading to CsA exposure higher than that predicted by C2 monitoring alone. Nephrology, Dialysis, Transplantation, 20(8), 1745-1747. [More Information]
  • Gallagher, M., Hall, B., Craig, J., Berry, G., Tiller, D., Eris, J. (2004). A Randomized Controlled Trial Of Cyclosporine Withdrawal In Renal-Transplant Recipients: 15-Year Results. Transplantation, 78(11), 1653-1660.
  • Cass, A., Devitt, J., Preece, C., Cunningham, J., Anderson, K., Snelling, P., Eris, J., Ayanian, J. (2004). Barriers To Access By Indigenous Australians To Kidney Transplantation: The Impakt Study. Nephrology, 9(Supplement 4), S144-S146.
  • Beckly, J., Bhandari, S., Eris, J., Horvath, J. (2003). The man who gained a stone. Nephrology, Dialysis, Transplantation, 18(2), 434-435.

Conferences

  • Ko, H., Yin, J., Hambly, B., Wyburn, K., Wu, H., Chadban, S., Eris, J. (2006). Rapamycin and Sanglifehrin A can inhibit interleukin-18 production from dendritic cells in vitro and in vivo. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Yin, J., Ko, H., Wyburn, K., Wu, H., Hambly, B., Chadban, S., Eris, J. (2006). The role of IL-12 family cytokines in chronic allograft nephropathy. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Wu, H., Chen, G., Wyburn, K., Afifi, M., Yin, J., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2006). TLR4 activation mediates kidney ischemia reperfusion injury. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Ko, H., Yin, J., Hambly, B., Wyburn, K., Wu, H., Chadban, S., Eris, J. (2005). Immunosuppressants rapamycin and sanglifehrin A inhibit bioactive IL-18 production by dendritic. 23rd Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Wyburn, K., Wu, H., Yin, J., Jose, M., Eris, J., Chadban, S. (2005). Interleukin-18 is elevated in experimental renal allograft rejection. 6th American Transplant Congress, Oxford, UK: Blackwell Publishing Professionals.
  • Yin, J., Wyburn, K., Wu, H., Chadban, S., Eris, J. (2005). The role of IL-18 and IL-12 family in chronic allograft nephropathy. 23rd Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Wu, H., Wyburn, K., Yin, J., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2005). Upregulation of NKG2D and it''s ligand RAE-1 in renal allografts may provide a link between innate and adaptive immunity in acute rejection. 6th American Transplant Congress, Oxford, UK: Blackwell Publishing Professionals.
  • Wu, H., Wyburn, K., Yin, J., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2005). Upregulation of NKG2D and its ligand RAE-1 in renal allografts may provide a link between innate and adaptive immunity in acute rejection. 23rd Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.

2014

  • Sud, R., Garry, L., Spicer, S., Allen, R., Eris, J., Wyburn, K., Verran, D., Cooper, C., Chadban, S. (2014). A role for everolimus in post-transplant encapsulating peritoneal sclerosis: First case report. Nephrology, 19(SUPPL. 1), 27-30. [More Information]

2013

  • Russ, G., Tedesco-Silva, H., Kuypers, D., Cohney, S., Langer, R., Witzke, O., Eris, J., Sommerer, C., Von Zur-Muhlen, B., Woodle, E., et al (2013). Efficacy of Sotrastaurin Plus Tacrolimus After De Novo Kidney Transplantation: Randomized, Phase II Trial Results. American Journal of Transplantation, 13(7), 1746-1756. [More Information]
  • Chadban, S., Eris, J., Russ, G., Campbell, S., Chapman, J., Pussell, B., Trevillian, P., Ierino, F., Thomson, N., Hutchison, B., et al (2013). Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients. Nephrology, 18(1), 63-70. [More Information]
  • Ko, H., Yin, J., Wyburn, K., Wu, H., Eris, J., Hambly, B., Chadban, S. (2013). Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction. Nephrology, Dialysis, Transplantation, 28(2), 327-336. [More Information]
  • Tedesco-Silva, H., Kho, M., Hartmann, A., Vitko, S., Russ, G., Rostaing, L., Budde, K., Campistol, J., Eris, J., Krishnan, I., et al (2013). Sotastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients. American Journal of Transplantation, 13(7), 1757-1768. [More Information]

2012

  • Chadban, S., Barraclough, K., Campbell, S., Clark, C., Coates, P., Cohney, S., Cross, N., Eris, J., Henderson, L., Howell, M., O'Connell, P., Webster, A., Wong, G., et al (2012). KHA-CARI guideline: KHA-CARI Adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Nephrology, 17(3), 204-214. [More Information]

2010

  • Gallagher, M., Kelly, P., Jardine, M., Perkovic, V., Cass, A., Craig, J., Eris, J., Webster, A. (2010). Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. Journal of the American Society of Nephrology, 21(5), 852-858. [More Information]
  • Hardy, J., Hambly, B., Ko, H., Wyburn, K., Eris, J., Yin, J. (2010). Stimulation of Mesangial Cells by Angiotensin II and Lipopolysaccharide Increases Expression of Interleukin-18, but Not IL-18 Receptor. Nephron Journals, 116(4), e63-e71. [More Information]

2009

  • Gallagher, M., Jardine, M., Perkovic, V., Cass, A., McDonald, S., Petrie, J., Eris, J. (2009). Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 87(12), 1877-1883. [More Information]
  • Low, T., Clark, J., Gao, K., Eris, J., Shannon, K., O'Brien, C. (2009). Outcome of parathyroidectomy for patients with renal disease and hyperparathyroidism: predictors for recurrent hyperparathyroidism. ANZ Journal of Surgery, 79(5), 378-382. [More Information]
  • Jardine, M., Bhandari, S., Wyburn, K., Misra, A., McKenzie, P., Eris, J. (2009). Photopheresis therapy for problematic renal allograft rejection. Journal of Clinical Apheresis, 24(4), 161-169. [More Information]

2008

  • Ko, H., Hambly, B., Eris, J., Levidiotis, V., Wyburn, K., Wu, H., Chadban, S., Yin, J. (2008). Dentritic cell derived IL-18 production is inhibited by rapamycin and sanglifehrin A, but not cyclosporine A. Transplant Immunology, 20(1-2), 99-105. [More Information]

2007

  • Tedesco-Silva, H., Vitko, S., Pascual, J., Eris, J., Magee, J., Whelchel, J., Civati, G., Campbell, S., Alves-Filho, G., Bourbigot, B., et al (2007). 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transplant International, 20(1), 27-36. [More Information]
  • Chadban, S., Baines, L., Polkinghorne, K., Jeffreys, A., Dogra, S., Kanganas, C., Irish, A., Eris, J., Walker, R. (2007). Anemia After Kidney Transplantation Is Not Completely Explained by Reduced Kidney Function. American Journal of Kidney Diseases, 49(2), 301-309. [More Information]
  • Cass, A., Cunningham, J., Anderson, K., Snelling, P., Colman, S., Devitt, J., Preece, C., Eris, J. (2007). Decision-making about suitability for kidney transplantation: Results of a national survey of Australian nephrologists. Nephrology, 12(3), 299-304. [More Information]
  • Wu, H., Chen, G., Wyburn, K., Bertolino, P., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2007). TLR4 activation mediates kidney ischemia/reperfusion injury. Journal of Clinical Investigation, 117(10), 2847-2859. [More Information]

2006

  • Cunningham, J., Cass, A., Anderson, K., Snelling, P., Devitt, J., Preece, C., Eris, J. (2006). Australian nephrologists' attitudes towards living kidney donation. Nephrology, Dialysis, Transplantation, 21(5), 1178-1183. [More Information]
  • Salvadori, M., Budde, K., Charpentier, B., Klempnauer, J., Nashan, B., Pallardo, L., Eris, J., Schena, F., Eisenberger, U., Rostaing, L., et al (2006). FTY720 versus MMF with cyclosporine in de novo renal transplantation: A 1-year, randomized controlled trial in Europe and Australasia. American Journal Of Transplantation, 6(12), 2912-2921.
  • Rose, B., Wilkins, D., Li, W., Tran, N., Thompson, C., Cossart, Y., McGeechan, K., O'Brien, C., Eris, J. (2006). Human Papillomavirus in the Oral Cavity of Patients with and without Renal Transplantation. Transplantation, 82(4), 570-573. [More Information]
  • Wyburn, K., Wu, H., Chen, G., Yin, J., Eris, J., Chadban, S. (2006). Interleukin-18 affects local cytokine expression but does not impact on the development of kidney allograft rejection. American Journal Of Transplantation, 6(11), 2612-2621. [More Information]
  • Ko, H., Yin, J., Hambly, B., Wyburn, K., Wu, H., Chadban, S., Eris, J. (2006). Rapamycin and Sanglifehrin A can inhibit interleukin-18 production from dendritic cells in vitro and in vivo. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Campistol, J., Eris, J., Oberbauer, R., Friend, P., Hutchison, B., Morales, J., Claesson, K., Stallone, G., Russ, G., Rostaing, L., et al (2006). Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. Journal of the American Society of Nephrology, 17(2), 581-589.
  • Eris, J., Russ, G., Hutchison, B., Walker, R., Chapman, J., Pussell, B., Mahoney, J., Campbell, S., Brault, Y., Burke, J., et al (2006). Sirolimus therapy after early cyclosporine withdrawal reduces the risk of malignancy at 5 years after renal transplantation. Immunology and Cell Biology, 84(3), A19-A19.
  • Yin, J., Ko, H., Wyburn, K., Wu, H., Hambly, B., Chadban, S., Eris, J. (2006). The role of IL-12 family cytokines in chronic allograft nephropathy. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.
  • Wu, H., Chen, G., Wyburn, K., Afifi, M., Yin, J., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2006). TLR4 activation mediates kidney ischemia reperfusion injury. 24th Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand (2006), Australia: Nature Publishing Group.

2005

  • Eris, J. (2005). Clinical experience with everolimus (Certican) in young renal transplant recipients. Transplantation, 79(9). [More Information]
  • Krämer, B., Neumayer, H., Stahl, R., Pietrzyk, M., Krüger, B., Pfalzer, B., Bourbigot, B., Campbell, S., Whelchel, J., Eris, J., et al (2005). Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab. Transplantation Proceedings, 37(3), 1601-1604. [More Information]
  • Ko, H., Yin, J., Hambly, B., Wyburn, K., Wu, H., Chadban, S., Eris, J. (2005). Immunosuppressants rapamycin and sanglifehrin A inhibit bioactive IL-18 production by dendritic. 23rd Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Kusyk, T., Verran, D., Stewart, G., Ryan, B., Fisher, J., Tsacalos, K., Chadban, S., Eris, J. (2005). Increased risk of hemorrhagic complications in renal allograft recipients receiving systemic heparin early posttransplantation. Transplantation Proceedings, 37(2), 1026-1028. [More Information]
  • Wyburn, K., Wu, H., Yin, J., Jose, M., Eris, J., Chadban, S. (2005). Interleukin-18 is elevated in experimental renal allograft rejection. 6th American Transplant Congress, Oxford, UK: Blackwell Publishing Professionals.
  • Wyburn, K., Wu, H., Yin, J., Jose, M., Eris, J., Chadban, S. (2005). Macrophage-derived interleukin-18 in experimental renal allograft rejection. Nephrology, Dialysis, Transplantation, 20(4), 699-706. [More Information]
  • Morales, J., Campistol, J., Kreis, H., Mourad, G., Eris, J., Schena, F., Grinyo, J., Nanni, G., Andres, A., Castaing, N., et al (2005). Sirolimus-Based Therapy With or Without Cyclosporine: Long-Term Follow-up in Renal Transplant Patients. Transplantation Proceedings, 37(2), 693-696. [More Information]
  • Russ, G., Segoloni, G., Oberbauer, R., Legendre, C., Mota, A., Eris, J., Grinyó, J., Friend, P., Lawen, J., Hartmann, A., et al (2005). Superior Outcomes in Renal Transplantation after Early Cyclosporine Withdrawal and Sirolimus Maintenance Therapy, Regardless of Baseline Renal Function. Transplantation, 80(9), 1204-1211. [More Information]
  • Yin, J., Wyburn, K., Wu, H., Chadban, S., Eris, J. (2005). The role of IL-18 and IL-12 family in chronic allograft nephropathy. 23rd Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.
  • Yu, R., Chadban, S., Svara, F., Sen, S., Eris, J. (2005). Two cases of delayed cyclosporin absorption leading to CsA exposure higher than that predicted by C2 monitoring alone. Nephrology, Dialysis, Transplantation, 20(8), 1745-1747. [More Information]
  • Wu, H., Wyburn, K., Yin, J., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2005). Upregulation of NKG2D and it''s ligand RAE-1 in renal allografts may provide a link between innate and adaptive immunity in acute rejection. 6th American Transplant Congress, Oxford, UK: Blackwell Publishing Professionals.
  • Wu, H., Wyburn, K., Yin, J., Eris, J., Alexander, S., Sharland, A., Chadban, S. (2005). Upregulation of NKG2D and its ligand RAE-1 in renal allografts may provide a link between innate and adaptive immunity in acute rejection. 23rd Annual Scientific Meeting of the Transplantation Society of Australia and New Zealand, Australia: Wiley-Blackwell Publishing Asia Pty Ltd.

2004

  • Gallagher, M., Hall, B., Craig, J., Berry, G., Tiller, D., Eris, J. (2004). A Randomized Controlled Trial Of Cyclosporine Withdrawal In Renal-Transplant Recipients: 15-Year Results. Transplantation, 78(11), 1653-1660.
  • Cass, A., Devitt, J., Preece, C., Cunningham, J., Anderson, K., Snelling, P., Eris, J., Ayanian, J. (2004). Barriers To Access By Indigenous Australians To Kidney Transplantation: The Impakt Study. Nephrology, 9(Supplement 4), S144-S146.

2003

  • Beckly, J., Bhandari, S., Eris, J., Horvath, J. (2003). The man who gained a stone. Nephrology, Dialysis, Transplantation, 18(2), 434-435.

To update your profile click here. For support on your academic profile contact .